These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27082062)

  • 1. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.
    Cheng AL; Thongprasert S; Lim HY; Sukeepaisarnjaroen W; Yang TS; Wu CC; Chao Y; Chan SL; Kudo M; Ikeda M; Kang YK; Pan H; Numata K; Han G; Balsara B; Zhang Y; Rodriguez AM; Zhang Y; Wang Y; Poon RT
    Hepatology; 2016 Sep; 64(3):774-84. PubMed ID: 27082062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
    Motzer RJ; Porta C; Vogelzang NJ; Sternberg CN; Szczylik C; Zolnierek J; Kollmannsberger C; Rha SY; Bjarnason GA; Melichar B; De Giorgi U; Grünwald V; Davis ID; Lee JL; Esteban E; Urbanowitz G; Cai C; Squires M; Marker M; Shi MM; Escudier B
    Lancet Oncol; 2014 Mar; 15(3):286-96. PubMed ID: 24556040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
    Cainap C; Qin S; Huang WT; Chung IJ; Pan H; Cheng Y; Kudo M; Kang YK; Chen PJ; Toh HC; Gorbunova V; Eskens FA; Qian J; McKee MD; Ricker JL; Carlson DM; El-Nowiem S
    J Clin Oncol; 2015 Jan; 33(2):172-9. PubMed ID: 25488963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
    Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
    Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
    World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
    Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
    Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
    Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Piscaglia F; Baron A; Park JW; Han G; Jassem J; Blanc JF; Vogel A; Komov D; Evans TRJ; Lopez C; Dutcus C; Guo M; Saito K; Kraljevic S; Tamai T; Ren M; Cheng AL
    Lancet; 2018 Mar; 391(10126):1163-1173. PubMed ID: 29433850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
    Thomas MB; Garrett-Mayer E; Anis M; Anderton K; Bentz T; Edwards A; Brisendine A; Weiss G; Siegel AB; Bendell J; Baron A; Duddalwar V; El-Khoueiry A
    Oncology; 2018; 94(6):329-339. PubMed ID: 29719302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
    Johnson PJ; Qin S; Park JW; Poon RT; Raoul JL; Philip PA; Hsu CH; Hu TH; Heo J; Xu J; Lu L; Chao Y; Boucher E; Han KH; Paik SW; Robles-Aviña J; Kudo M; Yan L; Sobhonslidsuk A; Komov D; Decaens T; Tak WY; Jeng LB; Liu D; Ezzeddine R; Walters I; Cheng AL
    J Clin Oncol; 2013 Oct; 31(28):3517-24. PubMed ID: 23980084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.
    Abdel-Rahman O; Abdel-Wahab M; Shaker M; Abdel-Wahab S; Elbassiony M; Ellithy M
    Med Oncol; 2013; 30(3):655. PubMed ID: 23824645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
    J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
    Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF
    Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study.
    Kim HY; Lee DH; Lee JH; Cho YY; Cho EJ; Yu SJ; Kim YJ; Yoon JH
    BMC Cancer; 2018 Mar; 18(1):307. PubMed ID: 29558905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.
    Escudier B; Grünwald V; Ravaud A; Ou YC; Castellano D; Lin CC; Gschwend JE; Harzstark A; Beall S; Pirotta N; Squires M; Shi M; Angevin E
    Clin Cancer Res; 2014 Jun; 20(11):3012-22. PubMed ID: 24691021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.
    Pressiani T; Boni C; Rimassa L; Labianca R; Fagiuoli S; Salvagni S; Ferrari D; Cortesi E; Porta C; Mucciarini C; Latini L; Carnaghi C; Banzi M; Fanello S; De Giorgio M; Lutman FR; Torzilli G; Tommasini MA; Ceriani R; Covini G; Tronconi MC; Giordano L; Locopo N; Naimo S; Santoro A
    Ann Oncol; 2013 Feb; 24(2):406-411. PubMed ID: 23041587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
    Trials; 2014 Dec; 15():474. PubMed ID: 25472660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review.
    Zhang X; Yang XR; Huang XW; Wang WM; Shi RY; Xu Y; Wang Z; Qiu SJ; Fan J; Zhou J
    Hepatobiliary Pancreat Dis Int; 2012 Oct; 11(5):458-66. PubMed ID: 23060390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
    Llovet JM; Decaens T; Raoul JL; Boucher E; Kudo M; Chang C; Kang YK; Assenat E; Lim HY; Boige V; Mathurin P; Fartoux L; Lin DY; Bruix J; Poon RT; Sherman M; Blanc JF; Finn RS; Tak WY; Chao Y; Ezzeddine R; Liu D; Walters I; Park JW
    J Clin Oncol; 2013 Oct; 31(28):3509-16. PubMed ID: 23980090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study.
    Woei-A-Jin FJSH; Weijl NI; Burgmans MC; Fariña Sarasqueta A; van Wezel JT; Wasser MNJM; Coenraad MJ; Burggraaf J; Osanto S
    Oncologist; 2021 Oct; 26(10):854-864. PubMed ID: 34251745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.